NasdaqGM:BCAXBiotechs
A Look At Bicara Therapeutics (BCAX) Valuation After New Ficerafusp Alfa Survival Data And Phase 3 Progress
Bicara Therapeutics (BCAX) shares are in focus after the company released three-year follow-up data for its lead candidate ficerafusp alfa in combination with pembrolizumab in recurrent or metastatic HPV-negative head and neck cancer.
See our latest analysis for Bicara Therapeutics.
At a latest share price of $20.00, Bicara’s short term performance has been mixed, with the 7 day share price return down 7.32% and the 30 day share price return down 11.97%. However, the year to date share price...